AN INTEGRATED BUSINESS MODEL
Our integrated business model has allowed us to build a portfolio of differentiated clinical and pre-clinical assets as well as a robust commercial portfolio.
Our deep understanding of vaccine science, our proven R&D capabilities and manufacturing infrastructure have been established to develop and commercialize our two successful travel vaccines. We are currently focusing our R&D capabilities on our vaccine candidates against Lyme disease, chikungunya and COVID-19.
Deep understanding of vaccine science
Valneva’s development programs benefit from its deep understanding of vaccine science including its expertise across multiple vaccine modalities.
Valneva’s R&D capabilities comprise all key functions needed to support the development of vaccines to licensure. Our R&D operations encompass more than 200 employees, most of whom are located in Vienna (Austria).
Manufacturing expertise and infrastructure
Valneva’s manufacturing network has been operating and producing licensed vaccines for more than 10 years and the Company believes it has the expertise and capability to produce most types of viral or bacterial vaccines.
Marketing & Distribution network
Valneva has developed a commercial presence in many key travel vaccine markets (Read more). The Company has also continued to leverage its commercial organization to distribute third-party products and aim to attract additional products to further leverage its commercial infrastructure.